Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema
- Sponsor
- Retina Clinic, Sao Paulo, Brazil
- Study ID
- NCT02623673
- Status
- Completed
Conditions
- Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
Study Details
Retrospective cases series is a non-randomized, open-label, single-center investigation (Retina Clinic, São Paulo, Brazil) of patients diagnosed with macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions who underwent to simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and implant of dexamethasone 0.7mg.
Key Dates
- First listed
- Dec 8, 2015
- Start date
- Sep 30, 2015
- Status verified
- Feb 2016
- Primary completion
- Dec 31, 2015
- Completion
- Feb 29, 2016
Study Design
- Enrollment
- 20 participants (actual)
Arms
- Arm: bevacizumab plus dexamethasone 0.7mgsimultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg
Primary Outcome Measure
Improvement in BCVA [ Time Frame: 6 months ]
Related Studies
- A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaPHASE2 · Recruiting · Boehringer Ingelheim · Arcadia, California